DPP4 and COVID-19: Several benefits of DPP4 inhibitors for patients with DM who develop COVID-19 have been proposed, including reduction of cytokine overproduction, downregulation of macrophage activity, enhancement of GLP-1 anti-inflammatory activity and stimulation of pulmonary anti-inflammatory effects [71].